Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Torkinib||PP242||mTOR Inhibitor 51||Torkinib (PP242) inhibits mTOR signaling through mTORC1/2, thereby preventing cell proliferation (PMID: 19209957).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastric adenocarcinoma||not applicable||Torkinib||Preclinical||Actionable||In a preclinical study, Torkinib (PP242) inhibited signaling of the PI3K/AKT/mTOR pathway and subsequent cell proliferation of gastric cancer cells in culture (PMID: 25035961).||25035961|
|ERBB2 amp||breast cancer||sensitive||Torkinib||Preclinical - Cell culture||Actionable||In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158).||27197158|
|Unknown unknown||multiple myeloma||not applicable||Torkinib||Preclinical - Patient cell culture||Actionable||In a preclinical study, Torkinib (PP242) treatment resulted in decreased mTORC2 signaling, growth inhibition and apoptosis in multiple myeloma cell lines and patient-derived multiple myeloma cells in culture, and reduced tumor growth in cell line xenograft animal models (PMID: 20686120).||20686120|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|